Agios Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up to $86 million in an initial public stock offering (IPO). The Cambridge, Massachusettsbased biotech, which develops treatments for cancer and inborn errors of metabolism (IEM), reportedly plans to use the IPO proceeds to fund clinical development of its lead product candidates in cancer and IEM programs. See Reuters.com, June 11, 2013.